Table 3 Dyspnoea, health-related quality of life and use of rescue medication up to Week 26
From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial
|  | NVA237 50 μg | Placebo |
|---|---|---|
TDI focal score | Â | Â |
   Least squares mean (± SE) | 1.84 ± 0.257 | 0.80 ± 0.294 |
   Least squares mean difference (± SE) | 1.04 ± 0.235 | |
   p-value | < 0.001 | |
SGRQ score | Â | Â |
   Baseline mean | 46.11 | 46.34 |
   Least squares mean (± SE) | 39.50 ± 0.813 | 42.31 ± 0.992 |
   Least squares mean difference (± SE) | -2.81 ± 0.961 | |
   p-value | 0.004 | |
Rescue medication use, puffs/day | Â | Â |
   LSM change from baseline (± SE) | -1.21 ± 0.122 | -0.75 ± 0.156 |
   Least squares mean difference (± SE) | -0.46 ± 0.164 | |
   p-value | 0.005 | |